Exploring the purine core of 3'-C-ethynyladenosine (EAdo) in search of novel nucleoside therapeutics

Bioorg Med Chem Lett. 2016 Apr 15;26(8):1970-2. doi: 10.1016/j.bmcl.2016.03.005.

Fabian Hulpia ¹, Jan Balzarini ², Dominique Schols ², Graciela Andrei ², Robert Snoeck ², Serge Van Calenbergh ³

Affiliations

1 Laboratory for Medicinal Chemistry, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium.
2 KU Leuven, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
3 Laboratory for Medicinal Chemistry, Ghent University, Ottergemsesteenweg 460, B-9000 Ghent, Belgium. Electronic address: Serge.VanCalenbergh@ugent.be.

PMID: 26965865 DOI: 10.1016/j.bmcl.2016.03.005

Abstract

A series of new nucleoside analogues based on a C-3 branched ethynyl sugar derivative as present in 3'-C-ethynylcytidine (ECyd) and -adenosine (EAdo), combined with modified purine Bases was synthetized and evaluated against a broad array of viruses and tumour cell lines. The pronounced cytostatic activity of EAdo was confirmed. EAdo and its 2,6-diaminopurine analogue showed inhibitory activity against vaccinia virus (EC50: 0.31 and 51 μM, respectively). Derivative 10 on the Other hand was found active against varicella zoster virus (EC50: 4.68 μM).

Keywords

3′-C-Ethynyladenosine; Nucleosides; Vorbrüggen coupling.

Name
Email *

	Sorry, but the email address you supplied was invalid.